English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine Clinical Trials
TrialWire Technology Platform Rolls Out World First SMS/Text Patient Contact System Across all Studies Globally
Jul 20, 2022 09:00 HKT
노보텍과 엔드포인트, “중국의 세포 및 유전자 치료의 진화: 범용성 CAR-T 사례”에 관해 발표
Jul 19, 2022 18:00 HKT
Therapeutic Goods Administration Grants Provisional Approval for Moderna's COVID-19 Vaccine in Children Aged Six Months to Five Years
Jul 19, 2022 11:00 HKT
Novotech和Endpoints展示“中国细胞和基因治疗的演变:通用CAR-T的案例”
Jul 19, 2022 07:00 HKT
Novotech和Endpoints展示“中國細胞和基因治療的演變:通用CAR-T的案例”
Jul 19, 2022 07:00 HKT
Novotech and Endpoints Present "Evolution of Cell & Gene Therapy in China: The Case for Universal CAR-T"
Jul 18, 2022 16:00 HKT
TrialWire Technology Platform Announces Success-based Patient Recruitment Plan
Jul 18, 2022 15:00 HKT
TrialWire(TM) 技术平台宣布基于成功的患者招募计划
Jul 18, 2022 15:00 HKT
TrialWire(TM) 技術平台宣布基於成功的患者招募計劃
Jul 18, 2022 15:00 HKT
노보텍 고객사 SK바이오사이언스, 스카이코비원(SKYCovione(TM)) 코로나19 백신 국내 승인
Jul 14, 2022 20:00 HKT
Novotech 客户 SK bioscience 在韩国获得 SKYCovione(TM) COVID-19 疫苗批准
Jul 14, 2022 08:00 HKT
Novotech 客戶 SK bioscience 在韓國獲得 SKYCovione(TM) COVID-19 疫苗批准
Jul 14, 2022 08:00 HKT
Novotech Client SK bioscience Achieves SKYCovione(TM) COVID-19 Vaccine Approval in Korea
Jul 13, 2022 14:30 HKT
노보텍, 2022 코리아 바이오프로세싱 엑설런스 어워드에서 ‘2022년 최고 바이오로직스 CRO 어워드’ 수상
Jun 29, 2022 19:00 HKT
Novotech Receives "Best Biologics CRO Award 2022" at Korea Bioprocessing Excellence Awards 2022
Jun 29, 2022 07:00 HKT
Novotech在2022年韩国生物工艺卓越奖中获得“2022年最佳生物制剂CRO奖”
Jun 29, 2022 07:00 HKT
Novotech在2022年韓國生物工藝卓越獎中獲得“2022年最佳生物製劑CRO獎”
Jun 29, 2022 07:00 HKT
노보텍, 고객의 기대를 뛰어넘는 성과로 CRO 리더십 상 수상
Jun 24, 2022 21:00 HKT
Novotech Receives CRO Leadership Award for Exceeding Customer Expectations
Jun 23, 2022 08:00 HKT
Novotech 因超出客户期望而获得 CRO 领导奖
Jun 23, 2022 08:00 HKT
<< Previous  Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: